Rheumatology
From the Journals
Biologics show signs of delaying arthritis in psoriasis patients
Treatment with the interleukin-12/23 inhibitor ustekinumab or interleukin-23 inhibitors (guselkumab, risankizumab, tildrakizumab) was linked to a...
News from the FDA/CDC
FDA approves first biologic treatment for polymyalgia rheumatica
The interleukin-6 receptor antagonist sarilumab (Kevzara) will be indicated in adults who have had an inadequate response to corticosteroids or...
From the Journals
Isolated nail psoriasis may bring arthritis into play
The review of 20 years of cases show delayed diagnosis, delineate clinical features, and suggest a relationship with PsA.
From the Journals
Bacteremia, antibodies link periodontal disease to RA development and activity
Researchers found frequent and repeated episodes of oral bacteria in the blood of patients with periodontal disease and rheumatoid arthritis, in a...
Feature
What’s holding back physicians from prescribing biosimilars? Four specialties weigh in
Physicians surveyed from four different specialties reported that they were generally comfortable prescribing biosimilars, but greater discounts...
Feature
How to recognize and treat hidden inflammation
IgG4-associated inflammation can affect one or more organs or the surrounding connective tissue and cause fibrosis.
Conference Coverage
Are repeat radiographs necessary in rheumatoid and psoriatic arthritis?
“If a patient doesn’t achieve remission or very low disease activity, obtaining a radiograph doesn’t change what you do because the patient’s not...
Conference Coverage
New tool better estimates cardiovascular risk in people with lupus
A tool to estimate cardiovascular risk in systemic lupus erythematosus incorporates disease-specific variables.
Conference Coverage
PsA prediction tool approaches clinical utility
A tool to identify patients with psoriasis at high risk of psoriatic arthritis appears near to clinical application.
Feature
Health plans get very poor scores for access to autoimmune drugs
Three out of four insurance plans use policies that result in significant to severe restriction of access to medications for seven autoimmune...
Conference Coverage
Two biomarkers identify high-risk lupus nephritis
Two biomarkers, elastase-DNA and HMGB1-DNA, correlate with poor outcomes in patients with lupus nephritis.